Trial intelligence / Profile preview

Cabazitaxel in Relapsed High‑Risk Hormone‑Sensitive Prostate Cancer

2012-004412-55Phase 2Terminated

Sponsor: Azienda Provinciale per i Servizi Sanitari
Start: Sep 2013
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised trial of cabazitaxel in prostate cancer (PCa) (2 arms), sponsored by Azienda Provinciale per i Servizi Sanitari. Primary endpoint: Progression-free survival. Started Sep 2013; status: terminated.

Drugs

cabazitaxel

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on 2012-004412-55.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-004412-55.